Skip to main content
Log in

cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas

  • Correspondence
  • Published:
Acta Neuropathologica Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Aoki K, Nakamura H, Suzuki H, Matsuo K, Kataoka K, Shimamura T et al (2018) Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol 20:66–77. https://doi.org/10.1093/neuonc/nox132

    Article  PubMed  CAS  Google Scholar 

  2. Appay R, Dehais C, Maurage C-A, Alentorn A, Carpentier C, Colin C et al (2019) CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro Oncol 21:1519–1528. https://doi.org/10.1093/neuonc/noz124

    Article  PubMed  Google Scholar 

  3. Brand F, Forster A, Christians A, Bucher M, Thome CM, Raab MS et al (2020) FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas. Acta Neuropathol 139:175–192. https://doi.org/10.1007/s00401-019-02067-z

    Article  PubMed  CAS  Google Scholar 

  4. Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB et al (2018) cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. Acta Neuropathol 136:805–810. https://doi.org/10.1007/s00401-018-1913-0

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR et al (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:2481–2498. https://doi.org/10.1056/NEJMoa1402121

    Article  CAS  Google Scholar 

  6. Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA et al (2016) Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164:550–563. https://doi.org/10.1016/j.cell.2015.12.028

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Cimino PJ, Holland EC (2019) Targeted copy number analysis outperforms histological grading in predicting patient survival for WHO grade II/III IDH-mutant astrocytomas. Neuro Oncol. https://doi.org/10.1093/neuonc/noz052

    Article  PubMed  Google Scholar 

  8. Cimino PJ, Zager M, McFerrin L, Wirsching HG, Bolouri H, Hentschel B et al (2017) Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery. Acta Neuropathol Commun 5:39. https://doi.org/10.1186/s40478-017-0443-7

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Cohen A, Sato M, Aldape K, Mason CC, Alfaro-Munoz K, Heathcock L et al (2015) DNA copy number analysis of grade II–III and grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status. Acta Neuropathol Commun 3:34. https://doi.org/10.1186/s40478-015-0213-3

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Coons SW, Pearl DK (1998) Mitosis identification in diffuse gliomas: implications for tumor grading. Cancer 82:1550–1555

    Article  CAS  Google Scholar 

  11. Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P (1988) Grading of astrocytomas. A simple and reproducible method. Cancer 62:2152–2165. https://doi.org/10.1002/1097-0142(19881115)62:10%3c2152:aid-cncr2820621015%3e3.0.co;2-t

    Article  PubMed  CAS  Google Scholar 

  12. Duregon E, Bertero L, Pittaro A, Soffietti R, Ruda R, Trevisan M et al (2016) Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas. Oncotarget 7:21190–21198. https://doi.org/10.18632/oncotarget.8498

    Article  PubMed  PubMed Central  Google Scholar 

  13. Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H et al (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499–2508. https://doi.org/10.1056/NEJMoa1407279

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Giannini C, Scheithauer BW, Burger PC, Christensen MR, Wollan PC, Sebo TJ et al (1999) Cellular proliferation in pilocytic and diffuse astrocytomas. J Neuropathol Exp Neurol 58:46–53. https://doi.org/10.1097/00005072-199901000-00006

    Article  PubMed  CAS  Google Scholar 

  15. Hansen LJ, Sun R, Yang R, Singh SX, Chen LH, Pirozzi CJ et al (2019) MTAP lsoss promotes stemness in glioblastoma and confers unique susceptibility to purine starvation. Cancer Res 79:3383–3394. https://doi.org/10.1158/0008-5472.CAN-18-1010

    Article  PubMed  CAS  Google Scholar 

  16. Korshunov A, Casalini B, Chavez L, Hielscher T, Sill M, Ryzhova M et al (2019) Integrated molecular characterization of IDH-mutant glioblastomas. Neuropathol Appl Neurobiol 45:108–118. https://doi.org/10.1111/nan.12523

    Article  PubMed  CAS  Google Scholar 

  17. Li KK, Shi ZF, Malta TM, Chan AK, Cheng S, Kwan JSH et al (2019) Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks. Neuro Oncol Adv 1:vdz015. https://doi.org/10.1093/noajnl/vdz015

    Article  Google Scholar 

  18. Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C et al (2017) Announcing cIMPACT-NOW: the consortium to inform molecular and practical approaches to CNS tumor taxonomy. Acta Neuropathol 133:1–3. https://doi.org/10.1007/s00401-016-1646-x

    Article  PubMed  Google Scholar 

  19. Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C et al (2017) cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification. Brain Pathol 27:851–852. https://doi.org/10.1111/bpa.12457

    Article  PubMed  Google Scholar 

  20. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, World Health Organization, International Agency for Research on Cancer (2016) WHO classification of tumours of the central nervous system. International Agency For Research On Cancer, Lyon

    Google Scholar 

  21. Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A et al (2014) International society of neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 24:429–435. https://doi.org/10.1111/bpa.12171

    Article  PubMed  Google Scholar 

  22. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK et al (2016) The 2016 World Health Organization Classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1

    Article  PubMed  Google Scholar 

  23. Mirchia K, Snuderl M, Galbraith K, Hatanpaa KJ, Walker JM, Richardson TE (2019) Establishing a prognostic threshold for total copy number variation within adult IDH-mutant grade II/III astrocytomas. Acta Neuropathol Commun 7:121. https://doi.org/10.1186/s40478-019-0778-3

    Article  PubMed  PubMed Central  Google Scholar 

  24. Olar A, Wani KM, Alfaro-Munoz KD, Heathcock LE, van Thuijl HF, Gilbert MR et al (2015) IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas. Acta Neuropathol 129:585–596. https://doi.org/10.1007/s00401-015-1398-z

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. Phillips JJ, Aranda D, Ellison DW, Judkins AR, Croul SE, Brat DJ et al (2013) PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. Brain Pathol 23:565–573. https://doi.org/10.1111/bpa.12043

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Reis GF, Pekmezci M, Hansen HM, Rice T, Marshall RE, Molinaro AM et al (2015) CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II–III) astrocytomas. J Neuropathol Exp Neurol 74:442–452. https://doi.org/10.1097/NEN.0000000000000188

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Reuss DE, Mamatjan Y, Schrimpf D, Capper D, Hovestadt V, Kratz A et al (2015) IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol 129:867–873. https://doi.org/10.1007/s00401-015-1438-8

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Richardson TE, Sathe AA, Kanchwala M, Jia G, Habib AA, Xiao G et al (2018) Genetic and epigenetic features of rapidly progressing IDH-mutant astrocytomas. J Neuropathol Exp Neurol 77:542–548. https://doi.org/10.1093/jnen/nly026

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Roy DM, Walsh LA, Desrichard A, Huse JT, Wu W, Gao J et al (2016) Integrated genomics for pinpointing survival loci within arm-level somatic copy number alterations. Cancer Cell 29:737–750. https://doi.org/10.1016/j.ccell.2016.03.025

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  30. Shirahata M, Ono T, Stichel D, Schrimpf D, Reuss DE, Sahm F et al (2018) Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathol 136:153–166. https://doi.org/10.1007/s00401-018-1849-4

    Article  PubMed  CAS  Google Scholar 

  31. Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M et al (2015) Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 129:679–693. https://doi.org/10.1007/s00401-015-1409-0

    Article  PubMed  CAS  Google Scholar 

  32. Yang RR, Shi ZF, Zhang ZY, Chan AK, Aibaidula A, Wang WW et al (2019) IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations. Brain Pathol. https://doi.org/10.1111/bpa.12801

    Article  PubMed  Google Scholar 

  33. Yoda RA, Marxen T, Longo L, Ene C, Wirsching HG, Keene CD et al (2019) Mitotic index thresholds do not predict clinical outcome for IDH-mutant astrocytoma. J Neuropathol Exp Neurol. https://doi.org/10.1093/jnen/nlz082

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This paper has been reviewed by the Steering Committee and Clinical Advisory Panel of cIMPACT-NOW [18, 19] and by the International Society of Neuropathology Executive. The authors would like to thank the participants of the cIMPACT-Utrecht meeting, who provided feedback and discussion on the conclusions and recommendations provided in this manuscript: David Capper, Ian Cree, Charles Eberhart, David Ellison, Christine Haberler, Cynthia Hawkins, HK Ng, Brent Orr, Sung-Hye Park, Werner Paulus, Torsten Pietsch, Marc Rosenblum, Brian Rous, Felix Sahm, David Solomon, Uri Tabori, Pieter Wesseling and Valerie White.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Daniel J. Brat.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 37 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brat, D.J., Aldape, K., Colman, H. et al. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol 139, 603–608 (2020). https://doi.org/10.1007/s00401-020-02127-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00401-020-02127-9

Navigation